v3.24.1.u1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments
Presented below is financial information with respect to the Company’s reportable segments for the periods presented:
Three Months Ended March 31,
20242023
Segment revenues:
Software$33,415 $32,213 
Drug discovery3,183 32,569 
Total segment revenues$36,598 $64,782 
Segment gross profit:  
Software$25,439 $25,098 
Drug discovery(6,549)20,595 
Total segment gross profit18,890 45,693 
Unallocated:  
Research and development(50,611)(40,741)
Sales and marketing(10,171)(9,145)
General and administrative(25,541)(26,308)
Gain on equity investments— 147,322 
Change in fair value8,137 35,737 
Other income5,028 2,937 
Income tax expense(456)(26,359)
Consolidated net (loss) income$(54,724)$129,136 
Schedule of Revenues by Geographic Area The following table sets forth revenues by geographic area for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
United States$23,297 $50,344 
APAC5,501 7,073 
EMEA7,196 6,828 
Rest of World604 537 
$36,598 $64,782